Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

A, Chari; DT, Vogl; M, Gavriatopoulou; AK, Nooka; AJ, Yee; CA, Huff; P, Moreau; D, Dingli; C, Cole; S, Lonial; M, Dimopoulos; AK, Stewart; J, Richter; R, Vij; S, Tuchman; MS, Raab; KC, Weisel; M, Delforge; RF, Cornell; D, Kaminetzky; JE, Hoffman; LJ, Costa; TL, Parker; M, Levy; M, Schreder; N, Meuleman; L, Frenzel; M, Mohty; S, Choquet; G, Schiller; RL, Comenzo; M, Engelhardt; T, Illmer; P, Vlummens; C, Doyen; T, Facon; L, Karlin; A, Perrot; K, Podar; MG, Kauffman; S, Shacham; L, Li; S, Tang; C, Picklesimer; JR, Saint-Martin; M, Crochiere; H, Chang; S, Parekh; Y, Landesman; J, Shah; PG, Richardson; S, Jagannath

doi:10.1056/nejmoa1903455

Public

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

Shared by NobleBlocks on Aug 1, 2019 • 12:00 AM UTC

Authors:

Chari A

Vogl DT

Gavriatopoulou M

Abstract

Background Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA translation, is a potential novel treatment for myeloma ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!